–(BUSINESS WIRE)–ReAlta Life Sciences, Inc. is a clinical stage biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. To support its vision, ReAlta has developed a novel class of therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates, and is also being developed as a treatment for acute lung injury secondary to COVID-19. The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.
|
Company: |
ReAlta Life Sciences, Inc. |
|
|
|
|
|
|
Headquarters Address: |
5665 Lowery Road |
|
|
|
Norfolk, VA 23502 |
|
|
|
|
|
|
Main Telephone: |
7579010460 |
|
|
|
|
|
|
Website: |
||
|
|
|
|
|
Type of Organization: |
Private |
|
|
|
|
|
|
Industry: |
Pharmaceutical |
|
|
|
|
|
|
Key Executives: |
CEO: Ulrich Thienel |
|
|
|
|
|
|
Public Relations |
|
|
|
Contact: |
Alicia Davis |
|
|
Phone: |
(910) 620-3302 |
|
|
Email: |
